HOME   |    PDF   |   


Title

Molecular docking analysis of lupeol with different cancer targets

Authors

Mahalakshmi Gunasekaran*, Ravali Ravi & Kavimani Subramanian

 

Affiliation

Department of Pharmacology, College of Pharmacy, Mother Theresa Post Graduate and Research Institute of Health Science, Pondicherry University, Puducherry-605006, India; *Corresponding author

 

Email

Mahalakshmi Gunasekaran - E-mail: mahamaya2603@gmail.com

Kavimani Subramanian - E-mail: drskavimani@yahoo.co.in

Ravali Ravi- E-mail: raviravali97@gmail.com

 

Article Type

Research Article

 

Date

Received January 3, 2022; Revised March 30, 2022; Accepted March 31, 2022, Published March 31, 2022

 

Abstract

Lupeol is one of the secondary metabolite (triterpenoid) present in many medicinally effective plants. It has numerous biological and pharmacological actions. Lupeol is found to have effective herbs and has immense biological activity against several diseases including its cytotoxic effect on cancer cells. In recent drug designing, molecular study of analysis is usually used for understanding the target and the ligand interaction. Therefore, it is of interest to document the molecular docking analysis data of lupeol with different cancer targets such as Caspase- 3, BCL-2, Topoisomerase, PTK, mTOR, H-Ras, PI3K, AKT. These molecular docking studies were carried out by using AutoDock tools 4.2 version software. Molecular docking analyses of lupeol with target protein were found to have good dock score and minimum inhibition constant. BCL-2, Topoisomerase, PTK, mTOR and PI3Kdocking studies showed the best binding energy inhibition constant and ligand efficiency. The in-silico molecular docking analysis showed that the lupeol having relatively good docking energy, affinity and efficiency towards the active macromolecule, thus it may be considered as good inhibitor of proliferating cancer cells. By this knowledge of docking results, the lupeol can be used as promising drug for anticancer activity.

 

Keywords

Molecular docking, lupeol, cancer targets

 

Citation

Gunasekaran et al. Bioinformation 18(3): 134-140 (2022)

 

Edited by

P Kangueane

 

ISSN

0973-2063

 

Publisher

Biomedical Informatics

 

License

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.